China’s Nanjing King-Friend Biochemical Pharmaceutical is paying $95m to increase its share in US generic injectables specialist Meitheal Pharmaceuticals to a majority stake, the two companies have announced.
Conducted through NKF’s wholly-owned subsidiary Hong Kong King-Friend Industrial Company, the deal is expected to close in the fourth quarter of 2019, and will see Meitheal